209 related articles for article (PubMed ID: 18695118)
1. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
[No Abstract] [Full Text] [Related]
2. Off-label use of bevacizumab in retinopathy of prematurity.
Rishi E; Rishi P; Ratra D; Bhende M
Retina; 2009 Feb; 29(2):284; author reply 284-5. PubMed ID: 18854784
[No Abstract] [Full Text] [Related]
3. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
[No Abstract] [Full Text] [Related]
4. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
Dorta P; Kychenthal A
Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
[TBL] [Abstract][Full Text] [Related]
5. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
6. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
[No Abstract] [Full Text] [Related]
7. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
8. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
Kychenthal A; Dorta P
Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
[TBL] [Abstract][Full Text] [Related]
9. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
[No Abstract] [Full Text] [Related]
10. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
Mintz-Hittner HA; Kuffel RR
Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
[TBL] [Abstract][Full Text] [Related]
11. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for retinopathy of prematurity.
Lim LS; Mitchell P; Wong TY
N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
[No Abstract] [Full Text] [Related]
13. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
Travassos A; Teixeira S; Ferreira P; Regadas I; Travassos AS; Esperancinha FE; Prieto I; Pires G; van Velze R; Valido A; Machado Mdo C
Ophthalmic Surg Lasers Imaging; 2007; 38(3):233-7. PubMed ID: 17552391
[TBL] [Abstract][Full Text] [Related]
14. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
Sato T; Kusaka S; Shimojo H; Fujikado T
Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
[TBL] [Abstract][Full Text] [Related]
15. [VEGF antibodies as therapy for retinopathy of prematurity].
Oberacher-Velten IM; Helbig H
Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
[TBL] [Abstract][Full Text] [Related]
16. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
17. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity.
Sato T; Shima C; Kusaka S
Am J Ophthalmol; 2011 Feb; 151(2):353-7.e1. PubMed ID: 21168819
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for retinopathy of prematurity.
Gilbert CE; Zin A; Darlow B
N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
[No Abstract] [Full Text] [Related]
19. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
20. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
Goldman DR; Baumal CR
J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
